Drug Profile
Research programme: neurological disorder therapies - Neurosciences Victoria
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Neurosciences Victoria
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Epilepsy; Multiple sclerosis; Neurological disorders; Parkinson's disease; Stroke
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Australia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Epilepsy in Australia